Global Castrate Resistant Prostate Cancer Therapeutics Market Insights, Forecast to 2028

Due to the COVID-19 pandemic, the global market for Castrate Resistant Prostate Cancer Therapeutics estimated at US$ 15,175.51 million in the year 2022, is projected to reach a revised size of US$ 28,717.44 million by 2028, growing at a CAGR of 11.22% during the forecast period 2022-2028.

The USA market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 6,215.82 million in 2022 to reach $ 11,706.05 million by 2028, at a CAGR of 10.89% during the forecast period of 2023 through 2028.

The China market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 1,224.11 million in 2022 to reach $ 2,596.61 million by 2028, at a CAGR of 13.25% during the forecast period of 2023 through 2028.

The Europe market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 4,273.15 million in 2022 to reach $ 8,083.69 million by 2028, at a CAGR of 10.92% during the forecast period of 2023 through 2028.

The global key companies of Castrate Resistant Prostate Cancer Therapeutics include Pfizer/Astellas(Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals, CTTQ, Sanofi, Hansoh, and Clovis Oncology, etc. In 2021, the global top five players had a share approximately 78.19 % in terms of revenue.

Report Includes

This report presents an overview of global market for Castrate Resistant Prostate Cancer Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Castrate Resistant Prostate Cancer Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Castrate Resistant Prostate Cancer Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Castrate Resistant Prostate Cancer Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Castrate Resistant Prostate Cancer Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Castrate Resistant Prostate Cancer Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals, CTTQ, Sanofi, Hansoh, and Clovis Oncology, etc.

Segment by Type

Hormonal Therapy
Chemotherapy
Others

Segment by Application

Hospital
Specialty Clinic
Others

By Company

Pfizer/Astellas(Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical

By Region

North America
- United States
- Canada

Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia

Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe

Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America

Middle East & Africa
- GCC Countries
- Turkey
- Egypt
- South Africa
- Others

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Castrate Resistant Prostate Cancer Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.

Chapter 9: Latin America by Type, by Application and by country, revenue for each segment.

Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Castrate Resistant Prostate Cancer Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

1 Report Overview

1.1 Study Scope
1.2 Market Analysis by Type
- 1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
- 1.2.2 Hormonal Therapy
- 1.2.3 Chemotherapy
- 1.2.4 Others
1.3 Market by Application
- 1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
- 1.3.2 Hospital
- 1.3.3 Specialty Clinic
- 1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends

2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2017-2028)
2.2 Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region
- 2.2.1 Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2017-2022)
- 2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics
- 2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
- 2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
- 2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges

3 Competition Landscape by Key Players

3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue
- 3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2017-2022)
- 3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2019-2022)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio
- 3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5)
- 3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2021
3.5 Castrate Resistant Prostate Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Castrate Resistant Prostate Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type

4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2023-2028)

5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application

5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028)
6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type
- 6.2.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022)
- 6.2.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028)
- 6.2.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application
- 6.3.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022)
- 6.3.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028)
- 6.3.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country
- 6.4.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022)
- 6.4.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2023-2028)
- 6.4.3 United States
- 6.4.4 Canada

7 Europe

7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028)
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type
- 7.2.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022)
- 7.2.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028)
- 7.2.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application
- 7.3.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022)
- 7.3.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028)
- 7.3.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country
- 7.4.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022)
- 7.4.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type
- 8.2.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022)
- 8.2.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028)
- 8.2.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application
- 8.3.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region
- 8.4.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia

9 Latin America

9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028)
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type
- 9.2.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022)
- 9.2.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028)
- 9.2.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application
- 9.3.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022)
- 9.3.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028)
- 9.3.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country
- 9.4.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022)
- 9.4.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028)
- 9.4.3 Brazil
- 9.4.4 Mexico
- 9.4.5 Argentina

10 Middle East & Africa

10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type
- 10.2.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022)
- 10.2.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028)
- 10.2.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application
- 10.3.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country
- 10.4.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028)
- 10.4.3 GCC Countries
- 10.4.4 Turkey
- 10.4.5 Egypt
- 10.4.6 South Africa

11 Key Players Profiles

11.1 Pfizer/Astellas(Xtandi)
- 11.1.1 Pfizer/Astellas (Xtandi) Company Details
- 11.1.2 Pfizer/Astellas(Xtandi) Business Overview
- 11.1.3 Pfizer/Astellas(Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.1.4 Pfizer/Astellas(Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.1.5 Pfizer/Astellas(Xtandi) Recent Development
11.2 Johnson & Johnson
- 11.2.1 Johnson & Johnson Company Details
- 11.2.2 Johnson & Johnson Business Overview
- 11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
11.3 AstraZeneca/Merck (Lynparza)
- 11.3.1 AstraZeneca/Merck (Lynparza) Company Details
- 11.3.2 AstraZeneca/Merck (Lynparza) Business Overview
- 11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.3.5 AstraZeneca/Merck (Lynparza) Recent Development
11.4 Bayer
- 11.4.1 Bayer Company Details
- 11.4.2 Bayer Business Overview
- 11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
11.5 Jiangsu Hengrui Pharmaceuticals
- 11.5.1 Jiangsu Hengrui Pharmaceuticals Company Details
- 11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.6 CTTQ
- 11.6.1 CTTQ Company Details
- 11.6.2 CTTQ Business Overview
- 11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.6.5 CTTQ Recent Development
11.7 Sanofi
- 11.7.1 Sanofi Company Details
- 11.7.2 Sanofi Business Overview
- 11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.7.5 Sanofi Recent Development
11.8 Hansoh
- 11.8.1 Hansoh Company Details
- 11.8.2 Hansoh Business Overview
- 11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.8.5 Hansoh Recent Development
11.9 Clovis Oncology
- 11.9.1 Clovis Oncology Company Details
- 11.9.2 Clovis Oncology Business Overview
- 11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
- 11.9.5 Clovis Oncology Recent Development
11.10 Zhendong Pharmaceutical
- 11.10.1 Zhendong Pharmaceutical Company Details
- 11.10.2 Zhendong Pharmaceutical Business Overview
- 11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
- 11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES

Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Chemotherapy
Table 4. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2017-2022)
Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2023-2028)
Table 10. Castrate Resistant Prostate Cancer Therapeutics Market Trends
Table 11. Castrate Resistant Prostate Cancer Therapeutics Market Drivers
Table 12. Castrate Resistant Prostate Cancer Therapeutics Market Challenges
Table 13. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (2019-2022) & (US$ Million)
Table 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2019-2022)
Table 15. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2021)
Table 16. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2021
Table 17. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5) & (2019-2022)
Table 18. Key Players Headquarters and Area Served
Table 19. Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service
Table 20. Date of Enter into Castrate Resistant Prostate Cancer Therapeutics Market
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 23. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2017-2022)
Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2023-2028)
Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2017-2022)
Table 28. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 29. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2023-2028)
Table 30. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 31. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 32. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 33. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 34. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 37. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 38. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 39. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 40. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 42. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 43. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 44. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 45. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 46. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 47. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 48. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 49. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 50. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 51. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 52. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 53. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 54. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 55. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 56. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 57. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 58. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 59. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 60. Pfizer (Xtandi) Company Details
Table 61. Astellas (Xtandi) Company Details
Table 62. Pfizer (Xtandi) Business Overview
Table 63. Astellas(Xtandi) Business Overview
Table 64. Pfizer/Astellas(Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product
Table 65. Pfizer/Astellas(Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 66. Pfizer/Astellas(Xtandi) Recent Development
Table 67. Johnson & Johnson Company Details
Table 68. Johnson & Johnson Business Overview
Table 69. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product
Table 70. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 71. AstraZeneca (Lynparza) Company Details
Table 72. Merck (Lynparza) Company Details
Table 73. AstraZeneca (Lynparza) Business Overview
Table 74. Merck (Lynparza) Business Overview
Table 75. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product
Table 76. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 77. AstraZeneca/Merck (Lynparza) Recent Development
Table 78. Bayer Company Details
Table 79. Bayer Business Overview
Table 80. Bayer Castrate Resistant Prostate Cancer Therapeutics Product
Table 81. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 82. Jiangsu Hengrui Pharmaceuticals Company Details
Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 84. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product
Table 85. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 87. CTTQ Company Details
Table 88. CTTQ Business Overview
Table 89. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product
Table 90. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 91. CTTQ Recent Development
Table 92. Sanofi Company Details
Table 93. Sanofi Business Overview
Table 94. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product
Table 95. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 96. Sanofi Recent Development
Table 97. Hansoh Company Details
Table 98. Hansoh Business Overview
Table 99. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product
Table 100. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 101. Hansoh Recent Development
Table 102. Clovis Oncology Company Details
Table 103. Clovis Oncology Business Overview
Table 104. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product
Table 105. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 106. Clovis Oncology Recent Development
Table 107. Zhendong Pharmaceutical Company Details
Table 108. Zhendong Pharmaceutical Business Overview
Table 109. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product
Table 110. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million)
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type, 2017-2028 (US$ Million)
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2021 VS 2028
Figure 3. Hormonal Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Others Features
Figure 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Application, 2017-2028 (US$ Million)
Figure 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2021 VS 2028
Figure 8. Hospital Case Studies
Figure 9. Specialty Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered
Figure 12. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region: 2021 VS 2028
Figure 15. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2021
Figure 16. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2019 VS 2021)
Figure 17. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2021
Figure 18. North America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
Figure 20. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
Figure 21. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028)
Figure 22. United States Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
Figure 26. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
Figure 27. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028)
Figure 28. Germany Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
Figure 35. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
Figure 36. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2017-2028)
Figure 37. China Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
Figure 45. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
Figure 46. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028)
Figure 47. Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Argentina Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028)
Figure 52. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028)
Figure 53. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028)
Figure 54. GCC Countries Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Turkey Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Egypt Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. South Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. Pfizer/Astellas(Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 59. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 60. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 61. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 62. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 63. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 64. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 65. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 66. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 67. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed